M.D. Anderson Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count).
M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.
M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.
Top-decile sponsor footprint
M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,692 total, page 49 of 54
Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging
NCT00499382
Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia
NCT00509600
Biospecimen Collection in Assessing the Effect of Trametinib With or Without Uprosertib on Biomarkers in Patients With Persistent or Recurrent Endometrial Cancer Enrolled on Trial GOG02290
NCT02093546
Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer
NCT00388154
Topotecan, Ifosfamide and Carboplatin in Children and Young Adults With Solid Tumors
NCT00502892
Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients
NCT00526110
Influenza Vaccination in Patients Receiving Antineoplastic Therapy for Non-Hodgkin's Lymphoma
NCT00307710
A Mood Management Intervention for Pregnant Smokers
NCT00505869
Quantitative Diffusion and Fat Imaging of the Spine
NCT00498277
Taxotere/Temodar/Cisplatin Study in Melanoma Patients
NCT00527761
Vanguard Study for Head and Neck Cancer or Non-Small Cell Lung Cancer (NSCLC) Patients
NCT00352391
Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients
NCT00516269
Dietary Methionine Restriction Plus Temozolomide for Recurrent GBM
NCT00508456
Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)
NCT00493129
Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases
NCT00081159
A Phase II Study of CC-5013 in Myelofibrosis
NCT00087672
Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).
NCT00088218
PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP
NCT00088231
Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
NCT00290511
Locus of Control and Spirituality in Palliative Care Patients
NCT00477243
Mindfulness Relaxation Compared With Relaxing Music and Standard Symptom Management Education in Treating Patients Who Are Undergoing Chemotherapy For Newly Diagnosed Solid Tumors
NCT00086762
Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS
NCT00520468
Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients
NCT00323557
Evaluation of the Signa Excite 3.0 T MRI Excite for Detection and Characterization of Liver Lesions
NCT00527891
RAD001 in Recurrent Endometrial Cancer Patients
NCT00087685
Genetic Susceptibility in Migrant Farmworker Children
NCT00501280
Iressa Study in Patients With Salivary Gland Cancer
NCT00509002
Symptom-Related Cytokines in Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Patients
NCT00504920
ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin
NCT00054691
Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors
NCT00078845
Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia
NCT00081887
Contemporary Characteristics of Penile Cancer
NCT04996849
Chemoradiation-Induced Nausea and Emesis: Quality of Life
NCT00394602
Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A
NCT00221039
Tracking of Respiratory-Induced Tumor Motion Using Implanted Fiducials
NCT00500513
RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma
NCT00081874
Quality of Life of Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
NCT00459524
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer
NCT00093379
Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)
NCT00500240
Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes
NCT00451997
Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma
NCT00081861
Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients
NCT00661544
Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma
NCT00387023
A Study of Actonel for the Prevention of Bone Loss
NCT00452439
Colon Cancer Screening in First-Degree Relatives of Hispanic Colorectal Cancer (CRC) Patients
NCT00838318
Gemox as First and Second Line Therapy in Unknown Primary Cancer
NCT00353145
PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery
NCT00276523
Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer
NCT00479089
Effects of Methylphenidate Versus Sustained Release Methylphenidate on Cognitive Functioning
NCT00418691
Melatonin Postoperative Sleep Study in Breast Cancer Patients
NCT00506064
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 748 |
| Phase 2 | 971 |
| Phase 3 | 96 |
| Phase 4 | 28 |
Therapeutic Areas
What is open in the M.D. Anderson Cancer Center pipeline
549 recruiting of 2,692 indexed (20% open); 1,201 completed (45%).
Phase mix: 124 late (III/IV) vs 1,719 early (I/II) (early-phase heavy).
Top condition: Hematopoietic and Lymphoid Cell Neoplasm (44 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.